Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
On Thursday, UBS analyst Eliana Merle reaffirmed a Buy rating and a $582.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), following positive feedback from a healthcare professional regarding the adoption of the company’s Journavx medication. The stock, currently trading at $446.03, has analyst targets ranging from $330 to $621, with InvestingPro data showing the company commands a substantial market cap of $114.6 billion.
Merle’s confidence in Vertex is bolstered by insights from a high-volume anesthesiologist who operates within a substantial health system. This system encompasses 20 outpatient surgical centers and 5 inpatient hospitals. The anesthesiologist, who treats approximately 300 patients monthly for acute pain, began prescribing Journavx in early March 2025. Since then, the medication has been administered to 100-200 outpatient surgical cases, with an average treatment duration of about one week. As a prominent player in the Biotechnology industry, Vertex has demonstrated strong revenue growth of 9% over the last twelve months, reaching $11.1 billion, according to InvestingPro data.
The healthcare expert has not reported any significant issues concerning patient access or affordability, even as prescriptions transitioned from samples to retail pharmacy fills. Based on the current trajectory and the anesthesiologist’s plans to increase usage, the expectation is that Journavx prescriptions could reach several hundred or potentially over a thousand by the end of 2025.
The anesthesiologist’s experience indicates a notable reduction in opioid usage among patients treated with Journavx. Initial observations suggest a decrease of 25-30%, with the potential for reductions of up to 50%. This reduction in opioid dependency is a key factor in the continued support for the medication’s use in outpatient settings.
Merle’s reiteration of the Buy rating and price target for Vertex stock reflects the anticipated growth in Journavx prescriptions and its potential impact on the company’s performance. The positive outlook is based on the firsthand account of the anesthesiologist’s experience with the drug and its effectiveness in managing patients’ pain while reducing opioid consumption. Based on InvestingPro analysis, Vertex currently appears fairly valued, with a "GOOD" overall financial health score. Subscribers can access 10 additional ProTips and a comprehensive Pro Research Report, offering deeper insights into Vertex’s market position and growth potential.
In other recent news, Vertex Pharmaceuticals Incorporated reported expected annual sales between $11.9 billion and $12.0 billion, largely driven by its cystic fibrosis products, including the newly launched ALYFTREK in the United States. Erste Group downgraded Vertex’s stock rating from Buy to Hold, citing concerns over inventory management and high receivables, which they believe may impact the company’s financial health. Scotiabank (TSX:BNS) maintained a Sector Perform rating for Vertex, with a price target of $442.00, noting positive feedback from physicians on ALYFTREK but cautioning that market expectations might be overly optimistic. Stifel also kept a Hold rating with a price target of $494.00, emphasizing the significance of Vertex’s chronic pain management efforts and ongoing clinical trials. Meanwhile, Bernstein maintained a Market Perform rating with a $462.00 price target, highlighting the importance of the upcoming launch of Journavx for acute pain. H.C. Wainwright reaffirmed its Buy rating and $550.00 price target, citing strong commercial performance for Journavx and its broad adoption in hospital and retail settings. The No Pain Act, effective January 2025, is believed to have facilitated broader insurance coverage for Journavx, enhancing its market potential. Vertex’s ongoing Phase 3 study for diabetic peripheral neuropathy continues as planned, with strategies in place to address challenges in the trial design.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.